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Criteria for Reducing Unnecessary Testing for Herpes Simplex Virus,
Varicella-Zoster Virus, Cytomegalovirus, and Enterovirus in
Cerebrospinal Fluid Samples from Adults
Craig B. Wilen,a Cynthia L. Monaco,b Joan Hoppe-Bauer,e Ronald Jackups, Jr.,a,c Robert C. Bucelli,d Carey-Ann D. Burnhama,c
Department of Pathology and Immunology,a Department of Medicine, Division of Infectious Diseases,b and Departments of Pediatricsc and Neurology,d Washington
University School of Medicine in St. Louis, St. Louis, Missouri, USA; Department of Laboratories, Barnes-Jewish Hospital, St. Louis, Missouri, USAe
Excessive utilization of laboratory diagnostic testing leads to increased health care costs. We evaluated criteria to reduce unnec-
essary nucleic acid amplification testing (NAAT) for viral pathogens in cerebrospinal fluid (CSF) samples from adults. This is a
single-center split retrospective observational study with a screening cohort from 2008 to 2012 and a validation cohort from
2013. Adults with available results for herpes simplex virus 1/2 (HSV-1/2), varicella-zoster virus (VZV), cytomegalovirus (CMV),
or enterovirus (EV) NAAT with CSF samples between 2008 and 2013 were included (n 10,917). During this study, 1.3% (n
140) of viral NAAT studies yielded positive results. The acceptance criteria of>10 nucleated cells/l in the CSF of immunocom-
petent subjects would have reduced HSV-1/2, VZV, CMV, and EV testing by 63%, 50%, 44%, and 51%, respectively, from 2008 to
2012. When these criteria were applied to the 2013 validation data set, 54% of HSV-1/2, 57% of VZV, 35% of CMV, and 56% of
EV tests would have been cancelled. No clinically significant positive tests would have been cancelled in 2013 with this approach.
The introduction of a computerized order entry set was associated with increased test requests, suggesting that computerized
order sets may contribute to unnecessary testing. Acceptance criteria of>10 nucleated cells/l in the CSF of immunocompetent
adults for viral CSF NAAT assays would increase clinical specificity and preserve sensitivity, resulting in significant cost savings.
Implementation of these acceptance criteria led to a 46% reduction in testing during a limited follow-up period.
Nucleic acid amplification testing (NAAT) for viral etiologiesof central nervous system (CNS) infections provides rapid
diagnosis for optimization of therapy (1, 2). However, this testing
can be costly and may not always be used judiciously (3). In this
era of cost containment, with a growing emphasis on the optimal
use of diagnostic tests (4–8), we assessed ordering practices for
viral NAATwith cerebrospinal fluid (CSF) specimens. Our objec-
tive was to develop criteria to reduce unnecessary testing.
Herpes simplex virus 1 (HSV-1) is the most common treatable
cause of viral encephalitis (9), while three of the most commonly
identified causes of aseptic meningitis are herpes simplex virus 2
(HSV-2), varicella-zoster virus (VZV), and enteroviruses (EV)
(10, 11). In addition, cytomegalovirus (CMV) infections of the
CNS may be of clinical concern among immunocompromised
individuals (12). NAAT has become the gold standard for diagno-
sis of most viral CNS infections (1, 2).
Viral CSF NAAT has several important benefits. First, early
diagnosis enables adequate administration of antiviral treatment
for HSV-1/2, VZV, and CMV, if necessary. Second, while no tar-
geted EV therapies currently exist, utilization of NAAT for EV
diagnosis has been correlated with reductions in length of stay,
ancillary testing, antibiotic utilization, and costs in pediatric pop-
ulations (13, 14). However, utilization of viral NAAT assays in
cases with low pretest probabilitymay unnecessarily increase costs
while decreasing the positive predictive value of the testing (13,
15). Several previous studies evaluated the implementation of lab-
oratory screening criteria to reduce superfluous CSF NAAT for
HSV-1/2 (16, 17). However, those studies were restricted to HSV-
1/2 and had limited sample sizes.
Herein we describe a retrospective study of nearly 11,000 CSF
NAAT assays and we propose screening criteria for HSV-1/2,
VZV, CMV, and EV testing. Using data from 2008 to 2012, we
identified CSF characteristics with very high negative predictive
values for HSV-1/2, VZV, CMV, and EV.We then retrospectively
applied those screening criteria to CSF requests for a 1-year period
(2013), to assess the cost savings and impact of the proposed al-
gorithm. Finally, we describe the impact of implementation of the
acceptance criteria described herein.
(This workwas presented in part at the 49thAnnualMeeting of
the Academy of Clinical Laboratory Physicians and Scientists, San
Francisco, CA, May 30, 2014.)
MATERIALS AND METHODS
Study overview. Barnes-JewishHospital (BJH) is an urban, adult, tertiary
care hospital in St. Louis, MO. Data on all HSV-1/2, VZV, CMV, and EV
NAAT studies ordered at BJH between January 1, 2008, andDecember 31,
2013, were obtained from the laboratory information system. Data on
laboratory CSF characteristics and immune status were collected for all
subjects with positive NAAT results and either twice as many randomly
selected subjects with negative results (2008-2012 cohort) or 10% of all
subjects with negative results (2013 cohort). Subjects with negativeNAAT
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results were selected with a random number generator. Data on protein
levels, glucose levels, cell counts, and cell differential counts for the CSF
specimens were collected from the electronic medical record (EMR).
Postmortem samples and samples from individuals less than 18 years of
age were excluded. Individuals lacking CSF protein and/or cell count
data were excluded from analyses. CMV test results from May to Oc-
tober 2009 were not available, as those tests were performed elsewhere;
those results were excluded. For the purposes of analysis, positive
NAAT results from subjects who met the various acceptance criteria
were considered true-positive results. This study was approved by the
Washington University in St. Louis Institutional Review Board/Hu-
man Research Protection Office.
Criteria for defining immunocompromised subjects. Subjects were
classified as immunocompromised if theymet any of the following criteria
(defined a priori) at the time of test ordering: (i) HIV infection (indepen-
dent of CD4 cell count), (ii) oral or intravenous immunosuppressant
therapy, (iii) use of cytotoxic medications, including chemotherapy, (iv)
history of solid organ or bone marrow transplant, (v) aplastic anemia, or
(vi) primary immunodeficiency. To assess the risk of bias, the immune
status of all subjects with positive NAAT results and an equal number of
subjects with negative results was assessed by a second coder (n  244).
The kappa statistic for interrater reliability was 0.93.
Diagnostic testing. All viral NAAT assays were qualitative assays per-
formed at St. Louis Children’s Hospital virology laboratory (St. Louis,
MO). Prior to August 2008, HSV-1/2 was detected with a laboratory-
developed NAAT gel-based assay; after that time, it was detected with the
MultiCode-RTx HSV 1&2 kit (EraGen), which was validated internally
for use with CSF samples. VZV was detected with a laboratory-developed
NAAT assay with gel-based detection of the amplification product. Prior
to August 2009, CMV testing was performed with a laboratory-developed
NAATgel assay, as described previously (18); after August 2009, CMVwas
detected with a TaqMan real-time PCR assay (19). EV was detected after
July 2009 with the Xpert EV assay (GeneXpert; Cepheid) and prior to that
time by using an analyte-specific reagent assay on the SmartCycler system
(Cepheid). CSF cell countswere determined by automated flow cell digital
imaging (iQ200; Iris Diagnostics). White blood cell (WBC) differential
counts weremanually determined by counting up to 100 cells prepared by
cytocentrifugation. The reference ranges reported for CSF WBC counts
and protein concentrations were 0 to 5 cells/l and 15 to 45 ng/ml, respec-
tively. The reference ranges reported for CSF neutrophil and lymphocyte
frequencies were 40 to 80%and 0 to 6%, respectively. Reference ranges for
CSF glucose levels and red blood cell (RBC) counts were not reported.
Computerized physician order entry analysis. Computerized physi-
cian order entry (CPOE) implementation occurred for inpatient services,
excluding the emergency department, between July and October 2009.
Due to limitations of our EMR, it was not possible to accurately determine
patient locations at the time of sample collection. Therefore, samples from
the emergency department were included in the analysis, with the poten-
tial limitation of underestimating the effects of CPOE implementation on
ordering practices. Since CPOEwas implemented in different divisions of
the hospital at different times during the 4-month implementation pe-
riod, this period was excluded from analysis.
Cost analysis. Annual cost savings were determined by multiplying
the test price by the frequency of cancelled negative tests and the number
of negative tests ordered per year. The 2014 Centers for Medicare and
Medicaid Services (CMS)midpoint price was $64.70 for eachNAAT assay
evaluated here (http://www.cms.gov/Medicare/Medicare-Fee-for-Service
-Payment/ClinicalLabFeeSched/clinlab.html). As the viral NAAT samples
were sent out to an external laboratory, the variable cost of each NAAT
assay is proprietary information, although similar to the CMS midpoint
prices.
Statistical analysis. Two-tailed Mann-Whitney tests were used to
compare data. P values of 0.05 were considered significant. Statistical
analysis was performed using Prism GraphPad 6.0.
RESULTS
Subject demographics. During the study period (2008 to 2013),
the most commonly ordered CSF viral NAAT assays at BJH were
for HSV-1/2, VZV, CMV, and EV. We used data from 2008 to
2012 to evaluate the acceptance criteria and data from 2013 to
validate the optimal criteria. In 2008 to 2012, 8,668 tests were
performed, of which only 1.4% were reported as positive (Table
1). Of 4,799 HSV-1/2 tests from 4,297 subjects, 56 tests (1.2%)
were positive; 13 (0.27%)were positive for HSV-1 and 43 (0.91%)
were positive for HSV-2. Of 1,588 VZV tests from 1,456 subjects,
27 (1.7%) were positive. Of 1,428 CMV tests from 1,284 subjects,
20 (1.4%) were initially reported as positive. Of 956 EV tests from
935 subjects, 20 (2.1%) were positive.
For all four tests combined, subjects with negative results were
of similar ages (median, 52 years [interquartile range, 38 to 65
years]), compared with those with positive results (median, 51
years [interquartile range, 36 to 63 years]).However, in contrast to
HSV-1/2, VZV, and CMV results, EV-positive subjects were sig-
nificantly younger (median, 28 years [interquartile range, 25 to 36
years]) than EV-negative subjects (median, 52 years [interquartile
range, 36 to 64 years]; P  0.001), consistent with the known
epidemiology of EV (20).
Ordering practices. The low prevalence of positive results and
the variation in age between EV-positive and EV-negative subjects
prompted an evaluation of ordering practices. CPOE for inpatient
units was implemented throughout the hospital between July and
October in 2009. After CPOE implementation, clinicians could
request NAAT assays individually or from an order set that in-
cluded laboratory tests for pathogens of the central nervous sys-
tem. The order set included 14 options for infectious disease test-
ing, including HSV-1/2, VZV, CMV, and EVNAAT (order set A).
However, the order set was modified 22 months later and HSV-
1/2 was removed (for unclear reasons), while VZV, CMV, and EV
remained (order set B). This required clinicians to initiate a sepa-
rate HSV-1/2 NAAT order. HSV-1/2 NAAT orders increased 5%
TABLE 1 Frequency of testing and rates of positive viral NAAT results
with adult CSF samples (2008–2012)
Test and result No. (%) of samples Age (median [IQR])a (yr)
HSV-1/2
Negative 4,743 52 (38–65)
Positive 56b (1.1) 50 (37–63)
VZV
Negative 1,561 53 (40–65)
Positive 27 (1.7) 45 (36–57)
CMV
Negative 1,408 52 (39–64)
Positive 20 (1.4) 46 (39–63)
EV
Negative 956 52 (36–64)
Positive 20 (2.0) 28 (25–36)
Total
Negative 8,668 52 (38–65)
Positive 123 (1.4) 51 (36–63)
a IQR, interquartile range.
b Thirteen samples were positive for HSV-1 and 43 were positive for HSV-2.
Wilen et al.
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with order set A and then decreased back to pre-CPOE levels when
HSV-1/2 was removed from the order set (order set B). In con-
trast, orders for VZV, CMV, and EV (all included in both order
sets A and B) increased 62%, 62%, and 54%, respectively, over the
same time period (Fig. 1A). Interestingly, this increase in VZV,
CMV, and EV test ordering was associated with an 11% relative
decrease in positive NAAT results per month, suggesting that in-
creased ordering did not improve detection of viral CNS infec-
tions.
Given the discrepancy in age between EV-positive and EV-
negative subjects, we evaluated ordering practices for EV tests. EV
meningitis is seasonal, with predominance in the summer and
early autumn (20). Of the 20 EV-positive samples, 19 were col-
lected between April and October (Fig. 1B). One EV-positive test
result was noted in December, from an immunocompromised
subject with three previous EV-positive results in that calendar
year. In contrast to the seasonal prevalence of EVmeningitis (20),
EV test ordering practices did not exhibit seasonal variation.
Laboratory characteristics of NAAT-positive and NAAT-
negative CSF samples.We sought to assess laboratory character-
istics of CSF samples that correlated with positive NAAT results
for HSV-1/2, VZV, CMV, and EV, with the goal of establishing
laboratory acceptance criteria for viral NAAT. We retrospectively
assessed cases from 2008 to 2012 to screen the predictive values of
CSF protein levels, glucose levels, RBC counts, nucleated cell
counts, lymphocyte percentages, and neutrophil percentages for
viral NAAT results.
Viral CNS infections are typically associated with normal or
slightly decreased CSF glucose concentrations, elevated protein
contents, and lymphocyte-predominant pleocytosis (21). The
median protein concentration was greater for HSV-1/2-positive
subjects than for HSV-1/2-negative subjects (101 versus 43mg/dl;
P 0.002) (Fig. 2A). Similarly, VZV-positive subjects had increased
protein concentrations, compared to VZV-negative subjects (94.5
versus 45.0 mg/dl; P  0.002). However, there were no significant
differences in protein levels for subjects with positive versus negative
CMV (61.5 versus 62.0 mg/dl; P  0.99) and EV (48.0 versus 60.0
mg/dl; P 0.61) results, suggesting that these parameters would not
be broadly applicable viral NAAT inclusion criteria.
Median CSF glucose concentrations were significantly lower
in HSV-1/2-positive subjects than in HSV-1/2-negative sub-
jects (56.5 mg/dl versus 69.5 mg/dl; P 0.001). There were no
significant differences in glucose concentrations for subjects
with positive versus negative VZV, CMV, and EV results (Fig.
2B). However, median RBC counts were significantly higher in
HSV-1/2-positive subjects than in HSV-1/2-negative subjects
(25 versus 8.5 cells/l; P 0.029) (Fig. 2C), while RBC counts
were similar for subjects with positive versus negative VZV,
CMV, and EV results. Median CSF nucleated cell counts were
significantly higher for HSV-1/2-positive (250 versus 1.5 cells/
l; P  0.001), VZV-positive (87 versus 3.5 cells/l; P 
0.001), CMV-positive (11.5 versus 1.0 cells/l; P 0.019), and
EV-positive (113 versus 6.0 cells/l; P  0.001) subjects than
for the corresponding negative subjects (Fig. 2D).
The CSF specimens from HSV-1/2-positive subjects were rel-
atively lymphophilic, compared to those from HSV-1/2-negative
subjects (84.0% versus 67.5%; P  0.001) (Fig. 2E), while there
was no difference in neutrophil frequencies (Fig. 2F). The fre-
quencies of lymphocytes and neutrophils did not significantly dif-
ferentiate VZV-positive and VZV-negative subjects (Fig. 2E and
F). The CSF specimens from CMV-positive subjects had relative
lymphopenia, compared to those from CMV-negative subjects
(48.0% versus 78.0%; P  0.001). The CSF specimens from EV-
positive subjects had relative lymphopenia (60.0% versus 80.0%;
P  0.026) and neutrophilia (14.5% versus 3.0%; P  0.004),
compared to those from EV-negative subjects.
Screening of laboratory acceptance criteria. Based on our
findings and those of others (3, 16, 17, 22), we evaluated three
different laboratory acceptance criteria for HSV-1/2, VZV, CMV,
and EV, including (i) WBC counts of5 cells/l or protein con-
centrations of 50 mg/dl, (ii) CSF WBC counts of 5 cells/l,
and (iii) WBC counts of10 cells/l (Table 2). All three labora-
tory cutoff criteria were evaluated with or without automatic ac-
ceptance of immunosuppressed subjects; therefore, six different
acceptance criteria were assessed.
The least stringent acceptance criteria assessed required either
a WBC count of 5 cells/l or a protein concentration of 50
mg/dl. This would have resulted in acceptance of 88% of positive
samples (106/120 samples) and cancellation of 50%of negative sam-
ples (123/244 samples) (Table 2). Allowing for automatic acceptance
of immunosuppressed subjects increased the number of positive
samples accepted to 94% (113/120 samples), while it decreased the
number of cancelled specimens to 39% (94/244 samples).
Acceptance based solely on the finding of5 nucleated cells/l
adversely affected the number of positive samples accepted at 76%
(93/122 samples) when immune status was not considered; how-
ever, a WBC count threshold of5 cells/l and automatic accep-
FIG 1 Correlates of unnecessary viral NAAT with CSF samples. (A) Comput-
erized physician order entry (CPOE) for non-emergency department inpatient
orders and an accompanying CSF order set were implemented in the autumn
in 2009. VZV, CMV, and EV NAAT assays were in the order set, while the
HSV-1/2 assaywas not. Orders increased disproportionately (shown above the
bars) for tests in the order set. (B) Despite the seasonality of EVmeningitis, EV
orders were not seasonal, suggesting unnecessary testing.
Acceptance Criteria for Viral NAAT with CSF Samples
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tance of immunosuppressed subjects increased the acceptance
rate for positive samples to 93% (114/122 samples), with a cancel-
lation rate of 48% for negative specimens (117/244 samples). In-
creasing the WBC count acceptance criterion from5 cells/l to
10 cells/l with automatic acceptance of immunosuppressed
subjects had no effect on the number of positive specimens ac-
cepted (93% [114/133 samples]), while it further increased the
proportion of negative specimens cancelled from 48% to 55%
(135/244 samples).
Therefore, acceptance criteria based on CSF WBC counts of
10 cells/l with automatic acceptance of immunosuppressed
subjects maximized acceptance of positive specimens and cancel-
lation of negative specimens. These criteria would have resulted in
the cancellation of 7% of positive specimens (8/122 samples)
among 8,791 tests. These eight cancelled positive tests represent
three of 55 HSV-1/2-positive NAAT assays, one of 27 VZV-posi-
tive NAAT assays, and four of 20 CMV-positive NAAT assays.
Seven of these eight positive NAAT assays were deemed clinically
insignificant by the treating clinicians. No EV-positive results
would have been missed; however, if EV testing was restricted to
the EV season (April to October), then one positive specimen
would have been cancelled, while the proportion of negative tests
cancelled would have increased from 51% (20/39 tests) to 68%
(26/40 tests). The one missed EV-positive sample was from an
immunosuppressed subject with three previous EV-positive test
results in that calendar year, all of which occurred during the EV
season and were associated withWBC counts of10 cells/l. The
optimal acceptance criteria included testing specimens from all
immunosuppressed subjects and samples from immunocompe-
tent subjects with 10 cells/l, in addition to cancellation of EV
FIG 2 Cytological and biochemical correlates of viral NAAT results. (A) CSF protein levels were higher inHSV-1/2- andVZV-positive samples but not in CMV-
or EV-positive samples. (B) CSF glucose concentrations were lower in HSV-1/2-positive samples than in negative samples. (C) CSF RBC counts were higher in
HSV-1/2-positive samples than in negative samples. (D) CSF nucleated cell counts were higher in NAATHSV-1/2-, VZV-, CMV-, and EV-positive samples. (E)
CMV- and EV-positive samples had reduced CSF lymphocyte counts, relative to negative samples, while HSV-1/2-positive samples had relative lymphocytosis.
(F) EV-positive samples had increased CSF neutrophil counts, relative to EV-negative samples. Dashed lines, upper and lower limits (0 if not shown) of the
reference ranges. No reference range was established for CSF glucose levels. Solid line in panel D, proposed nucleated cell count acceptance criterion. Whiskers,
2.5% and 97.5% limits. Dots, outliers.
Wilen et al.
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testing outside the EV season. Using a CMS midpoint price of
$64.70 per test (http://www.cms.gov/Medicare/Medicare-Fee-for
-Service-Payment/ClinicalLabFeeSched/clinlab.html), apply-
ing these acceptance criteria would have resulted in laboratory
savings of $64,989 per year from 2008 to 2012 (Table 2).
Validation of laboratory acceptance criteria. Next, we retro-
spectively applied the laboratory acceptance criteria determined
with the 2008-2012 screening cohort to a 2013 validation cohort.
In 2013, 17 (0.80%) of 2,126 tests were positive for HSV-1/2 (n
9), VZV (n 5), CMV (n 2), or EV (n 1) (Table 3). Applying
the acceptance criteria of WBC counts of10 cells/l with auto-
matic acceptance of immunosuppressed subjects and EV testing
only from April to October would have resulted in the acceptance
of 88% of positive tests (15/17 tests). Of the two tests not auto-
matically accepted, one subject presented with acute appendicitis
and developed postoperative altered mental status, aphasia, and
right upper extremity weakness. He was ultimately diagnosed as
experiencing a cerebrovascular accident, and the positive HSV-2
result was deemed clinically insignificant after an infectious dis-
ease consultation. The second subject presented with headache
and vertigo and had a positive HSV-1 test result, which was
deemed clinically insignificant after an infectious disease consul-
tation. The patient was discharged with a diagnosis of migraine.
In addition to accepting all clinically significant true-positive
specimens in 2013, these acceptance criteria would have excluded
two clinically insignificant positive tests and 51% of negative tests
(111/217 tests). This would have saved $69,585, assuming the
CMSmidpoint prices, and improved the positive predictive value
of NAAT.
Implementation of laboratory acceptance criteria. We im-
plemented the aforementioned CSF NAAT acceptance criteria in
July 2014. Prior to implementation, we educated clinicians in the
departments of neurology, internal medicine, and emergency
medicine regarding the rationale and evidence for the acceptance
criteria. At the time of manuscript preparation, the acceptance
criteria had been in place for 137 days. We observed 16% fewer
NAAT orders than during the same period in 2013, suggesting
that our educational efforts might have been effective (Table
4). Thirty-six percent of requested tests were cancelled without
a clinician override. The overall reductions in the various
NAAT assays were 53%, 41%, 41%, and 38% for HSV, VZV,
CMV, and EV, respectively, compared to the same time period
in 2013. This corresponded to a 46% overall reduction in tests
performed, with a savings of $24,004 (based on CMS midpoint
pricing), which annualizes to $63,992. This is similar to the
51% of NAAT results that did not meet the acceptance criteria
in 2013 and the predicted annual savings of $69,585.
DISCUSSION
Establishing laboratory acceptance criteria for HSV-1/2, VZV,
CMV, and EV NAAT with CSF specimens may increase the posi-
tive predictive value of such tests (by increasing the pretest prob-
ability), improve patient care, and reduce health care costs. We
have demonstrated that acceptance criteria of 10 WBCs/l in
the CSF of immunocompetent patients would have reduced viral
NAAT assays by 51% in our hospital in 2013, which is similar to
the 46% reductionwe prospectively observed in a brief postimple-
mentation period. These acceptance criteria would have pre-
vented nine clinically insignificant or false-positive results during
a 6-year period, including oneHSV-1, threeHSV-2, oneVZV, and
four CMV results.
An important question regarding these data is as follows: why
are so many viral CSF NAAT assays ordered for patients without
pleocytosis? There are several potential explanations. First, the
costs of laboratory tests and the potential harm of false-positive
results may not be prioritized as highly as the potential harm
and medicolegal costs of failing to diagnose a treatable viral
infection of the CNS. Second, it may be more convenient for
clinicians to order NAAT assays prior to the availability of CSF
cell count, protein level, and glucose level results. Third, order
sets with comprehensive lists of potential etiologies may con-
tribute to nonselective ordering practices. This hypothesis is
TABLE 3 Validation of acceptance criteria (2013)
Test
No. % (no./total no.)
Cost





HSV-1/2 974 965 9 0 54 (51/95) 78 (7/9)a 33,518
VZV 485 480 5 0 57 (27/47) 100 (5/5) 17,841
CMV 429 427 2 0 35 (15/43) 100 (2/2) 9,637
EV 238 236 1 1 56 (18/32) 100 (1/1) 8,589
Total 2,126 2,108 17 1 51 (111/217) 88 (15/17)a 69,585
a In each case, both excluded tests were clinically insignificant, according to an infectious disease consultation.
TABLE 4 Effects of implementation of acceptance criteria
Parameter HSV-1/2 VZV CMV EV Total
No. of NAAT assays requested/performed in 2013 365 190 164 90 809
No. of NAAT assays requested in 2014 (% change from 2013) 294 (20) 166 (13) 139 (15) 83 (8) 682 (16)
No. of NAAT assays performed in 2014 (% change from 2013) 173 (53) 112 (41) 97 (41) 56 (38) 438 (46)
No. of NAAT assays rejected (% of requested) 121 (41) 54 (33) 42 (30) 27 (33) 244 (36)
Realized savings ($) 12,422 5,047 4,335 2,200 24,004
Annualized savings ($) 33,117 13,454 11,556 5,864 63,992
Wilen et al.
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supported by the fact that we determined that the inclusion of
VZV, CMV, and EV tests in an order set correlated with an
approximate 60% increase in testing. Fourth, there may be a
misperception of the clinical utility and/or cost-effectiveness of
viral NAAT, particularly for EV.
As no specific antiviral therapy for EV meningitis exists, the
rationale for testing among adults is extrapolated from pediat-
ric studies, in which EV-positive results were associated with
reduced antibiotic use, length of stay, and admission costs (14,
23). A subsequent study suggested that EV testing was cost-
effective for children only with an EV prevalence of greater
than 5.9%, in contrast to the 1.7% described for our patient pop-
ulation (13). There are several limitations in extrapolating the pedi-
atric data to adults (23). First, the prevalence of CNS EV infections
among adults is less than that among children (20). Second, using
positive EV NAAT results to exclude concurrent alternative infec-
tious etiologies, as is done in the pediatric population, may not be
appropriate for adults. Additional studies are required to determine
whether the rationale used in pediatric care can be extrapolated to
adult populations.
Implementation of the described acceptance criteria would
have reduced NAAT results considered clinically insignificant by
the treating providers. Of the three HSV-1/2-positive subjects
whose testing would have been cancelled based on the algorithm
described, one subject, who tested positive for HSV-2 in the CSF,
presented with 1 month of altered mental status and recent
genital herpes. A second subject had NAAT results positive for
HSV-2 but was deemed to have experienced a cerebrovascular
accident. The HSV-2 results for both subjects were clinically
considered to be false-positive results at the time, after infec-
tious disease consultation. A third subject presented with fever
and aphasia and subsequently was treated for HSV-1 encepha-
litis after positive NAAT results were obtained. This sample
would have been cancelled under all six acceptance criteria
evaluated; however, clinical suspicion was high enough to war-
rant treatment (see discussion below). The one missed VZV-
positive subject presented with an acute unilateral headache.
Two days after lumbar puncture, a pathognomonic vesicular
rash emerged in the V1 distribution, and then NAAT of the
preexisting CSF specimen was requested.
Of the four CMV-positive specimens that would have been
cancelled, results for two subjects were determined to be clinically
insignificant after infectious disease consultation. One CMV-pos-
itive subject was discharged without regard for the positive result,
and antiviral therapywas not initiated. The fourthCMV specimen
that would have been excluded was from a previously healthy
young female patient who presented with lower extremity weak-
ness. She was discharged with a diagnosis of CMV transverse my-
elitis. She returned 10 months later with an exacerbation, despite
having received adequate therapy for CMV, and ultimately was
diagnosed with multiple sclerosis.
While the acceptance criteria we describe may effectively re-
duce costs and unnecessary testing, the importance of appropriate
clinical judgment cannot be overstated. Among the 10,981 tests
performed, the criteria described hereinmay have resulted in can-
cellation of one test from a case of potential HSV-1 encephalitis.
This subject had other signs of HSV-1 infection, including a pro-
drome of fever, headache, and malaise followed by aphasia,
apraxia, and memory impairment. Furthermore, magnetic reso-
nance imaging of the brain demonstrated findings concerning for
HSV-1 encephalitis, with the left insula and anterior temporal
cortex demonstrating increased T2 signal, diffusion restriction,
and parenchymal contrast enhancement. However, there was no
evidence of hemorrhage or leptomeningeal enhancement. The
CSF specimen exhibited a protein concentration of 41 mg/dl, a
glucose concentration of 84 mg/dl (with a blood glucose concen-
tration of 140mg/dl), 5 nucleated cells/l, with 85% lymphocytes,
12% monocytes, and 3% neutrophils, and 453 RBCs/l. While
this case only meets the criteria proposed by Bhaskaran et al.
for a possible true-positive result (15), the severity of HSV-1
encephalitis warrants antiviral treatment even without a defin-
itive laboratory-based diagnosis. It should be noted that de-
layed administration of acyclovir may worsen patient out-
comes and thus mitigate or negate cost savings. Additionally, it
is important to note that a negative NAAT result does not rule
out HSV-1/2 encephalitis, as NAAT results can be negative
early in the course of illness (24). These data illustrate the im-
portance of a streamlined process for “physician override” of
algorithmic testing approaches for patients with clinical signs
and symptoms consistent with a specific diagnosis, to facilitate
testing when it is clinically warranted.
To fully capture the cost savings of the described acceptance
criteria and to reduce the erroneous cancellation of testing for
specimens meeting the acceptance criteria, efficient and accurate
implementation is essential. While the automatic assessment of
CSF nucleated cell counts can be easily integrated by laboratory
information systems, the assessment of immune status is more
challenging for laboratory personnel and/or building into a
laboratory information system algorithm. Currently in our
hospital, specimens received from locations where all patients
are immunosuppressed are automatically accepted. For the re-
maining specimens, the microbiology resident or fellow on call
assesses each specimen for the acceptance criteria. This is done
once daily 7 days per week, immediately prior to the batched
sending out of NAAT specimens, and generally requires only 1
to 2 min per sample. For samples that do not meet the accep-
tance criteria, a comment appears in the EMR with the reason
for cancellation and a laboratory contact telephone number for
automatic override if the clinical suspicion remains strong. All
cancelled specimens are held for 30 days for additional testing
if needed. A more automated implementation approach would
include enabling clinicians to communicate the patient’s im-
mune status at the time of order entry, either through a check
box or with separate CSF NAAT order sets for immunocompe-
tent and immunosuppressed patients.
Our limited prospective follow-up monitoring after imple-
mentation of the NAAT acceptance criteria was associated with a
46% reduction in NAAT assays. While this was predominantly
due to the laboratory rejecting testing of specimens not meeting
the set criteria, there was a 16% reduction in provider orders for
these tests. This may be due to a combination of our educational
efforts and increased awareness of ordering practices. Future ob-
servation is warranted, to determinewhether this change in order-
ing frequency is sustainable, especially in the setting of an aca-
demic medical center.
The strengths of this study include the comparison of various
acceptance criteria and the inclusion of four commonly ordered
NAAT assays, namely, those for HSV-1/2, VZV, CMV, and EV.
For HSV-1/2, we assessed more positive samples than the three
prior studies evaluating this clinical issue combined (16, 17, 22).
Acceptance Criteria for Viral NAAT with CSF Samples
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Previous acceptance criteria for HSV-1/2 based on CSF WBC
counts alone or in combination with CSF protein concentrations
have been reported (16, 17). Our data suggest that the CSF protein
concentration provides little, if any, additive prognostic value
when the CSF WBC count is known (data not shown). In our
patient population, overemphasis on elevated CSF protein con-
centrations may contribute to unnecessary test ordering. We also
demonstrate the importance of considering a patient’s immune
status in applying the acceptance criteria, as 20% of the positive
NAAT tests (25/122 tests) were from immunocompromised sub-
jects who lacked pleocytosis.
This study has several limitations. First, we report data from a
single urban tertiary care center. While our patient population is
diverse, our findings may not be able to be extrapolated to other
medical centers or other patient populations, such as children.
Second, institution-specific ordering practices may affect our low
prevalence of positive results. Third, this is a retrospective study
that may inherently introduce selection and misclassification bi-
ases, although the degree of such biases is likelyminimal, given the
data collection methods and high interrater correlation. Fourth,
despite our large sample size, the number of positive tests is low
overall. Finally, no CSF acceptance criteria maintained sufficient
sensitivity in the absence of accounting for patient immune status.
While acceptance criteria based on WBC counts can be auto-
mated in laboratories, assessment of immunocompetence is
difficult to automate; therefore, immune status may best be
indicated by the ordering provider on the test requisition or
assessed by skilled laboratory personnel. New informatics and
communication methods that engage ordering providers in al-
gorithmic testing may increase the efficiency of applying NAAT
acceptance criteria.
In conclusion, there are critical demands for health care cost
containment and quality improvement (4–8). Establishing lab-
oratory acceptance criteria for viral NAAT of CSF samples is
one example of an approach to both reducing costs and im-
proving patient care by reducing unnecessary testing and its
associated consequences.
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